Table 1.
Baseline characteristics of all patients receiving study treatment.
| Characteristic | Value |
|---|---|
| Age, years | |
| Mean | 68 |
| Range | 51–79 |
| ECOG, number (%) | |
| 0 | 17 (38) |
| 1 | 27 (60) |
| 2 | 1 (2) |
| Total alkaline phosphatase | |
| Median, IU/l | 99.0 |
| Range, IU/l | 39–964 |
| Haemoglobin | |
| Median, g/dl | 13.3 |
| Range, g/dl | 9.7–15.9 |
| PSA | |
| Median, ng/ml | 16.8 |
| Range, ng/ml | 2.1–907.3 |
| Extent of disease, bone metastasesa (%) | |
| <6 | 23 (51.1) |
| 6–20 | 15 (33.3) |
| >20 | 9 (19.1) |
| Duration of ADT, years | |
| Median | 4.3 |
| Range | (0.5–18.8) |
| Bone health agentsb, number (%) | |
| Denosumab | 7 (15.6) |
| Zoledronic acid | 19 (42.2) |
a
Two patients did not receive study treatment.
b
Received prior to study entry.
ADT, androgen deprivation therapy; ECOG, Eastern Cooperative Oncology Group; PSA, prostate specific antigen.